share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股sec公告 ·  07/01 08:08
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.
NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.
生物技術公司神經感知治療有限公司於2024年7月1日宣佈了其爲肌萎縮性側索硬化症（ALS）提供治療的PrimeC的12個月PARADIGM 2b期研究的重要發現。該研究表明，與安慰劑組相比，接受PrimeC治療的參與者疾病進展得到了36％的改善，生存率提高了43％。結果還顯示在符合治療方案分析中，生存率提高了63％，這表明了PrimeC作爲一種疾病修正藥物的潛力。神經感知目前正在計劃在美國和歐洲進行第3期臨床研究。該公司的策略是專注於開發針對多途徑神經退行性疾病的治療方法。PrimeC已被授予美國和歐盟的孤兒藥物認定。神經感知通過其網站和社交媒體渠道向投資者分發信息，建議投資者監控這些渠道以及SEC的文件和新聞發佈。
生物技術公司神經感知治療有限公司於2024年7月1日宣佈了其爲肌萎縮性側索硬化症（ALS）提供治療的PrimeC的12個月PARADIGM 2b期研究的重要發現。該研究表明，與安慰劑組相比，接受PrimeC治療的參與者疾病進展得到了36％的改善，生存率提高了43％。結果還顯示在符合治療方案分析中，生存率提高了63％，這表明了PrimeC作爲一種疾病修正藥物的潛力。神經感知目前正在計劃在美國和歐洲進行第3期臨床研究。該公司的策略是專注於開發針對多途徑神經退行性疾病的治療方法。PrimeC已被授予美國和歐盟的孤兒藥物認定。神經感知通過其網站和社交媒體渠道向投資者分發信息，建議投資者監控這些渠道以及SEC的文件和新聞發佈。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息